Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - CNS

368MO - Fatty acid synthase inhibitor TVB-2640 with bevacizumab in recurrent glioblastoma

Date

18 Sep 2020

Session

Mini Oral - CNS

Presenters

William Kelly

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

W. Kelly1, J. Michalek2, A.E. Diaz Duque3, V. Madhusudanannair3, L. Caflisch3, B. Konkel3, J. Floyd4, A.J. Brenner5

Author affiliations

  • 1 Hematology And Medical Oncology, Mays Cancer Center at the UT Health San Antonio, - - San Antonio/US
  • 2 Epidemiology And Biostatistics, UT Health San Antonio, 787229 - San Antonio/US
  • 3 Mays Cancer Center, UT Health San Antonio, 78229 - San Antonio/US
  • 4 Hematology And Medical Oncology, Mays Cancer Center at the UT Health San Antonio, 78229-3264 - San Antonio/US
  • 5 Institute For Drug Development, Mays Cancer Center at the UT Health San Antonio, 78229-3264 - San Antonio/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 368MO

Background

Standard of care for glioblastoma (GBM) is surgical resection followed by chemoradiation and tumor treatment fields, with bevacizumab (bev) given at relapse. Responses to bev remain brief; and resistance may involve overexpression of Fatty Acid Synthase (FASN).

Methods

We performed prospective phase 2 study of bev with oral FASN inhibitor TVB-2640 in patients with rGBM at first relapse. Primary end point was progression free survival (PFS) with comparison to bev single agent outcomes from BELOB. Inclusion criteria included adults with GBM progression following standard combined modality treatment. An exploratory phase randomization into 2 separate arms of single agent bev or in combination with TVB-2640 with MR-Spectroscopy (MRS) and serum sampling for exosome analysis was obtained on all patients at day 1 and 28 of first cycle. Starting on cycle 2 day 1, all patients converged to a single arm and continued to receive bev in combination with TVB-2640.

Results

A total of 28 patients were enrolled, 3 failed screening. 23 came off study and 2 are active. No grade 4 or higher treatment-related AEs have occurred, with Grade 3 events included 3 cases of palmar-plantar erythrodysesthesia; 1 each of hypertension, stomatitis, optic neuritis, DVT, and wound infection. A 66.7% overall response rate (ORR) was observed and 95% of patients have achieved at least stable disease by RANO Criteria. Median time to progression was 5.9m, which was statistically superior to historical controls. Median overall survival (OS) was 10.1m with an OS12 of 40%. Biomarker analysis (exosome, MRS) is pending.

Conclusions

The combination of TVB-2640 with bev appears well tolerated with improved progression free and overall survival compared to historical controls. Additional studies are warranted. Final data analysis as well as exploratory biomarker analysis will be presented.

Clinical trial identification

NCT03032484.

Editorial acknowledgement

Legal entity responsible for the study

Mays Cancer Center at UTHSA.

Funding

Kolitz and Johnson Endowments for Neuro-Oncology Research.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings